skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials

Simile, Maria Maddalena ; Bagella, Paola ; Vidili, Gianpaolo ; Spanu, Angela ; Manetti, Roberto ; Seddaiu, Maria Antonietta ; Babudieri, Sergio ; Madeddu, Giordano ; Serra, Pier Andrea ; Altana, Matteo ; Paliogiannis, Panagiotis

Medicina (Kaunas, Lithuania), 2019-02, Vol.55 (2), p.42 [Periódico revisado por pares]

Switzerland: MDPI

Texto completo disponível

Citações Citado por
  • Título:
    Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials
  • Autor: Simile, Maria Maddalena ; Bagella, Paola ; Vidili, Gianpaolo ; Spanu, Angela ; Manetti, Roberto ; Seddaiu, Maria Antonietta ; Babudieri, Sergio ; Madeddu, Giordano ; Serra, Pier Andrea ; Altana, Matteo ; Paliogiannis, Panagiotis
  • Assuntos: biliary tree ; cancer ; cholangiocarcinoma ; genomics ; molecular pathways ; Review ; targeted therapies
  • É parte de: Medicina (Kaunas, Lithuania), 2019-02, Vol.55 (2), p.42
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-3
    content type line 23
    ObjectType-Review-1
  • Descrição: Cholangiocarcinoma (CCA) is a highly-aggressive malignancy arising from the biliary tree, characterized by a steady increase in incidence globally and a high mortality rate. Most CCAs are diagnosed in the advanced and metastatic phases of the disease, due to the paucity of signs and symptoms in the early stages. This fact, along with the poor results of the local and systemic therapies currently employed, is responsible for the poor outcome of CCA patients and strongly supports the need for novel therapeutic agents and strategies. In recent years, the introduction of next-generation sequencing technologies has opened new horizons for a better understanding of the genetic pathophysiology of CCA and, consequently, for the identification and evaluation of new treatments tailored to the molecular features or alterations progressively elucidated. In this review article, we describe the potential targets under investigation and the current molecular therapies employed in biliary tract cancers. In addition, we summarize the main drugs against CCA under evaluation in ongoing trials and describe the preliminary data coming from these pioneering studies.
  • Editor: Switzerland: MDPI
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.